Could engineered immune cells tackle childhood cancers that Won't quit?

This early-stage study tests a new treatment called B7-H3 CAR T cells in up to 40 children and young adults whose solid tumors (like neuroblastoma) have come back or stopped responding to standard care. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a specific marker (B7-H3). The main goals are to see if the cells can be made safely and to find the best dose, while also monitoring side effects.